Comparison
Exenatide vs. Semax
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Research other
CAS no.
141758-74-9
80714-61-0
Molecular weight
4186.6 g/mol
813.92 g/mol
Half-life
2.4 h
0.3 h
Sequence
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSMet-Glu-His-Phe-Pro-Gly-ProMechanism of action
Exenatide
Exenatide is a 39-amino-acid peptide with about 53% sequence homology to human GLP-1. A glycine substitution at position 2 prevents dipeptidyl-peptidase-IV cleavage and extends the half-life from native GLP-1 (minutes) to about 2.4 hours. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon and delays gastric emptying.
Semax
Semax is a tetracosactide fragment analog without hormonal activity at MC2R. Proposed mechanisms include elevation of BDNF and NGF in hippocampus and striatum (in animal models), modulation of dopamine metabolism, and neuroprotective effects via anti-apoptotic pathways. A clear primary receptor is not established.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
5
4
of which in humans
4
2
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
2
1